PhoenixBio Co., Ltd.

6190

JP3803010002

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 12:32:11 2024-07-12 am EDT			5-day change	1st Jan Change
500 ^JPY	-0.40%		-4.94%	+7.30%

2023	PhoenixBio Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	CI
2022	PhoenixBio Co., Ltd. announced that it expects to receive ¥1.92 million in funding from Milestone Capital Management Co., Ltd.	CI

PhoenixBio Co., Ltd. announced that it has received ¥1.0009141 billion in funding from Whiz Partners Inc., and another investor

March 29, 2020

On March 30, 2020, PhoenixBio Co., Ltd. (TSE:6190) closed the transaction. The stock acquisition rights can be exercised from March 30, 2020 till December 29, 2023.

Latest news about PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-15	CI
PhoenixBio Co., Ltd. announced that it expects to receive ¥1.92 million in funding from Milestone Capital Management Co., Ltd.	22-05-12	CI
Inotiv, Inc. Announces Partnership with PhoenixBio Co., Ltd. to Expand Discovery Pharmacology Offering	21-04-06	CI
PhoenixBio Co., Ltd. announced that it has received ¥1.0009141 billion in funding from Whiz Partners Inc., and another investor	20-03-29	CI
PhoenixBio Co., Ltd. announced that it expects to receive ¥1.0009141 billion in funding from Whiz Partners Inc., and another investor	20-03-12	CI
PhoenixBio Co., Ltd. completed the acquisition of KMT Hepatech Inc. from a group of shareholders.	17-11-30	CI
PhoenixBio Co., Ltd. agreed to acquire KMT Hepatech Inc. from a group of shareholders for CAD 5.5 million.	17-11-13	CI
Certain shares of PhoenixBio Co., Ltd. are subject to a Lock-Up Agreement Ending on 13-SEP-2016.	16-09-12	CI
Certain warrants of PhoenixBio Co., Ltd. are subject to a Lock-Up Agreement Ending on 13-SEP-2016.	16-09-12	CI
PhoenixBio Co., Ltd. has completed an IPO in the amount of ¥984.00 million.	16-03-17	CI
PhoenixBio Co., Ltd. has filed an IPO.	16-02-15	CI

PhoenixBio Co., Ltd. is a Japan-based company mainly engaged in provision of contract research services of drug development, which uses PXB mouse. The PXB Mouse segment is engaged in the development of technology to create PXB Mouse in which more than 70% of mouse livers are replaced with human hepatocytes. The product called PXB Mouse is used in the preclinical process of the discovery of drugs.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q1 2024 Earnings Release

More about the company

	1st Jan change	Capi.
PHOENIXBIO CO., LTD.	+7.30%	12.75M
MODERNA, INC.	+23.52%	47.07B
LONZA GROUP AG	+46.45%	42.06B
IQVIA HOLDINGS INC.	-3.14%	39.98B
ALNYLAM PHARMACEUTICALS, INC.	+37.40%	33.02B
CELLTRION, INC.	-6.30%	27.9B
ICON PUBLIC LIMITED COMPANY	+19.53%	27.63B
UNITED THERAPEUTICS CORPORATION	+47.66%	14.37B
MEDPACE HOLDINGS, INC.	+44.42%	13.45B
BIO-TECHNE CORPORATION	+0.51%	12.03B

Other Biotechnology & Medical Research